DOCSLIB.ORG

MMR Vaccine, Thimerosal and Regressive Or Late Onset Autism (“Autistic Enterocolitis”) a Review of the Evidence for a Link Between Vaccination and Regressive Autism

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
MMR Vaccine, Thimerosal and Regressive Or Late Onset Autism (“Autistic Enterocolitis”) a Review of the Evidence for a Link Between Vaccination and Regressive Autism MMR Vaccine, Thimerosal and Regressive or Late Onset Autism (“Autistic Enterocolitis”) A Review of the Evidence for a Link Between Vaccination and Regressive Autism David Thrower, 49, Ackers Road, Stockton Heath, Warrington, England June 2005 email [email protected] Contents Executive Summary Part A: A Novel Syndrome 1. What Is Acquired Autism/Autistic Enterocolitis 2. The New Syndrome Part B: The Scale of the Autism Problem 3. The Financial Costs - Autism Is Costing The Taxpayer £$Billions 4. Overall Cost Estimates 5. Failure to Monitor Increases In UK Autism Numbers 6. “Now Almost Everyone Knows Someone Who’s Autistic” 7. Is Autism Increasing Due To Changes In Criteria? 8. Autistic Disorder 9. Pervasive Developmental Disorder Not Otherwise Specified 10. Asperger’s 11. Paper by Mark Blaxill, June 2001 12. University of Cambridge Research 13. University of Sunderland Research 14. UK National Autistic Society Estimates 15. Report by Fiona Loynes, UK All Party Parliamentary Group, Dec. 2001 16. Report, “Autism In Schools”, UK National Autistic Society May 2002 17. Autism in Scottish Schools 18. Is Autism Increasing? - Some Official UK Pronouncements 19. Autism In The USA 20. The US Amish Community 21. Autism Elsewhere Part C: MMR 22. The Introduction of MMR 23. Recognised Adverse Reactions to MMR 24. US Vaccine Adverse Events Reporting System (VAERS) 25. Contraindications To Receiving MMR 26. The UK Department of Health’s Position over MMR and Autism 27. Single Vaccines In The UK 28. Measles In The UK and US 29. Promotion of MMR In The UK After Wakefield “Early Report” 30. Position of the US Centers For Disease Control on MMR/Autism 31. The Parents Have Seen What They’ve Seen..... Part D: The Thimerosal/Thiomersal* Issue (*the two terms are interchangeable) 32. Thimerosal’s Possible Role 33. Joint Statement by American Acad. Of Ped./PH Service, July 1999 34. Removal of Thimerosal 35. Interview With Neal Halsey, Johns Hopkins University, Nov 2002 36. Waters & Kraus Press Release, 2002 37. Statement by Safe Minds group, US 38. US Use of Thimerosal - Statement by Dr. Geier, 2004 39. Thimerosal’s Use in the US 40. UK Vaccines With Thimerosal 41. UK Med. and Healthcare Regulatory Agency Position on Thimerosal 42. UK Joint C’ttee on Vaccin & Immunisation Position on Thimerosal 43. UK Department of Health’s Position on Thimerosal 44. US CDC Thimerosal Studies 45. Report, “Mercury In Medicines”, US C’ttee on Govt. Reform 2003 46. Letter to Congress by the US Office of Special Counsel, 2004 47. California Votes To Ban Thimerosal, June 2004 48. US CDC’s Current Position on Thimerosal 49. Memo by Merck Part E: Evidence That Autism Increases Are Real 50. Paper by Mark Blaxill, The Rising Incidence of Autism 51. Close-Up On California 52. The MIND Study, California 53. Close-Up On New Jersey 54. Atlanta Study, 2003 55. Paper by Gurney, Fritz et al, Trends on ASD In Minnesota, 2003 56. Paper by Yazbak, Autism In The US, J of A Phs & Surg 2003 57. Paper by Yazbak, Autism In Quebec, 2004 Part F: Reviews Questioning the Autism Epidemic 58. Paper by Fombonne, UK Med Research Council, Pediatrics, Jan 2001 59. Paper by Wing, Centre for Social & Commun. Disorders, London 2002 60. Position of Dr. B. S. Siegal, University of California, 2002 61. Study by Croen et al, July 2002 62. Editorial by Fombonne, J of the American Medical Asscn., January 2003 63. Paper by Jick et al, Boston Un Sch of Med, Pharmacotherapy, Dec 2003 64. Study by Smeeth, Fombonne et al, November 2004 65. Study by Barbarisi et al, January 2005 Part G: The MMR Original Safety Trials Debate 66. Wakefield & Montgomery “Through A Glass Darkly” (MMR safety) 67. Dr. Peter Fletcher Commentary, J of Adverse Drug Reactions, 2001 68. Dr. Stephen Dealler Commentary, J. of Adverse Drug Reactions, 2001 69. Dr. F. E. Yazbak Commentary, J of Adverse Drug Reaction, 2001 70. The Wakefield/Watson/Shattock Rebuttals 71. The UK Dept of Health’s Repudiation of “Through A Glass Darkly”. Part H: Studies and Papers That Point Towards The Plausibility Of Gut/Autism, MMR/Gut/Autism, Thimerosal/Autism and Autoimmunity/Autism Links 72. Paper by Nelson & Gottshall, Applied Microbiology, May 1967 73. Paper by Eggers, Klinical Paediatrics, March 1976 74 Weizman, Weizmann et al Study, Am. J of Psychiatry, Nov. 1982 75. Delgiudice-Asch and Hollander Study 76. Paper by Dr. H. Fudenberg 77. Paper by Dr. Reed Warren 78. Warren and Singh Study, Immunogenetics, 1992 79. Singh, Warren, Odell, Warren and Cole Paper, March 1993 80. Singh, Warren, Odell et al Study, Brain Behaviour, March 1993 81. Oleske and Zecca paper 82. Binstock paper 83. Anne-Marie Plesner Letter, Lancet, February 1995 84. Paper by Thompson, Montgomery et al, Lancet, April 1995 85. Gupta, Aggarwal & Heads Study, J of Autism and Dev Disorders, 1996 86. Montinari, Favoino and Roberto paper, Naples conference May 1996 87. Auwaerter & Griffin paper, Clin Immunol & Immunopath, May 1996 88. Cook, Courchesne et al Paper, Molecular Psychiatry, May 1996 89. Griffin and Hussy Study, Journal of Infectious Diseases, June 1996 90. Martinez et al Study, Proceedings of National Acad of Sciences, 1997 91. Paper by Zecca, Graffino et al, Meeting of Nat Inst of Health, Sept. 1997 92. Weibel, Caserta and Evans Study, March 1998 93. Wakefield et al “Early Report”, Lancet, February 1998 94. Paper by Montgomery, Morris et al (pub. date/details not yet known) 95. Sabra, Bellanti and Colon letter, Lancet, July 1998 96. Further Paper by Singh and Yang, Pharmaceutical Jnl, October 1998 97. Uhlmann, Sheils et al Paper 98. Bitnun et al Study, Clinical Infectious Diseases Journal, October 1999 99. Paper by Horvath, Papadimitriou et al, Journal of Pediatrics Nov 1999 100. Paper by Singh to the US Committee on Govt Reform, April 2000 101. O’Leary Paper Presented to Congressional Oversight C’ttee, April 2000 102. Kawashima, Takayuki et al Study, Digestive Dis and Sciences, Apr 2000 103. Confidential Review, US CDC, Simpsonwood, June 2000 104. Hagenbuch, Kullak-Ublick et al Study, J of Pharm Exp Ther, July 2000 105. Wakefield et al Paper, American J. of Gastroenterology, September 2000 106. Statement by Professor Walter O. Spitzer, December 2000 107. Furlano, Anthony et al Study, Journal of Pediatrics, 2001 108. Paper by Enayati et al, Medical Hypotheses, 2001 109. Study by Jyonouchi, Sun and Le, J. of Allergy & Clin. Immun., Feb. 2001 110. Study by Jyonouchi, Sun and Le, J of Neuroimmunology, 2001 111. Paper by Spitzer, Aitken et al, J of Adverse Drug Reactions & Tox., 2001 112. Study by Holmes, Cave et al, June 2001 113. Paper by Blaxill, Institute of Medicine, July 2004 114. Paper by Dr. Ken Aitken to the Scottish Society for Autism, 2001 115. Paper by Imani and Kehoe, Clinical Immunology, September 2001 116. Paper by Redwood, Bernard et al, Neurotoxicology, October 2001 117. Paper by Buie, Oasis 2001 Conference for Autism, Portland, US 118. Paper by Uhlmann, Wakefield et al, J. of Clinical Pathology, Feb. 2002 119. Paper by Singh and Nelson, February 2002 120. Review by Wakefield, Pulestone et al, Aliment Pharm. Ther. 2002 121. Report of Study, Comi et al, Johns Hopkins Hosp, Baltimore, Apr 2002 122. Paper by Torrente, Ashwood, Day et al, Lancet, May 2002. 123. Paper to 102nd GM of Am. Soc for Microbiology, Singh et al, May 2002 124. Study by O’Leary et al to Path Soc of GB and Ireland July 2002 125. Wakefield Paper Presented to US Govt Reform Committee, June 2002 126. Paper to US Government Reform C’ttee by Dr Krigsman, June 2002 127. Unpublished Research by Shattock, Un. of Sunderland, June 2002 128. Paper by Sheils, Smyth, Martin & O’Leary, Trinity Coll Dublin, 2002 129. Paper by Dr. Vijendra Singh, Utah State University, August 2002 130. Paper by Finegold, Molitoris, Song, J. Of Clin. Infect. Dis., Sept 2002 131. Further paper, Jyonouchi, Sun & Itokazu, Un. of Minnesota, Oct 2002 132. Paper, Treat. of Late Onset Autism, Matarazzo, U.S-Paulo, Nov 2002 133. Paper by Makani, Gollapudi et al, Genes & Immunity, 2002 134. Paper by Westphal, Asgari et al, Arch of Toxicology, August 2002 135. Unpublished letter by Wakefield to New Eng. J. of Medicine, Nov 2002 136. Study by Croonenberghs et al, University of Antwerp, December 2002 137. Paper by Holmes, Blaxill & Haley, Internat J of Toxicology 2003 138. Paper by Singh and Jensen, Pediatric Neurology 2003 139. Paper by Geier & Geier, Soc. for Experimental Biology & Med. 2003 140. Study by Geier and Geier, International Pediatrics, May 2003 141. Further Paper by Geier & Geier, Ped. Rehabilitation, Apr-June 2003 142. Further Paper by Geier & Geier, J of Am Phys and Surg, Spring 2003 143. Paper by Blaxill, Redwood & Bernard, Safe Minds 144. Paper by Bradstreet, Geier et al, J of Am Phy and Surg Summer 2003 145. Letter by Geier & Geier, J of Am Phys. & Surgeons, Summer 2003 146. Paper by Baskin, Ngo et al, Toxicology Science Aug 2003 147. Paper by Via, Nguyen et al, Envir. Health Perspectives August 2003 148. Paper by Sweeten, Bowyer et al, Pediatrics, November 2003 149. Paper by Ashwood, Murch et al, J of Clinical Immunology, Nov 2003 150. Study by Ueha-Ashibishi, Oyama et al, Toxicology, Jan 2004 151. Paper by Jyonouchi, Geng et al, Jan 2004 152. Paper by Singh, presented to the Inst. of Med, Washington, Feb 2004 153. Paper by Bradstreet, Inst of Medicine, Washington, Feb 2004 154. Paper by Bradstreet, O’Leary et al, Inst of Medicine, Feb 2004 155. Further Paper by Bradstreet, Institute of Medicine, Feb 2004 156. Presentation by Geier and Geier to the Institute of Medicine, Feb 2004 157.
Load more

Recommended publications
  • Applied Behaviour Analysis & the Treatment of Autism
    Applied Behaviour Analysis & the Treatment of Autism 1 Autism: Incidence Rates Happe (1998) suggested the figure common to most studies was between 4-10 per 10,000 births A number of authors have reported substantive and continuous increases in incidence rates Magnusson and Saemundsen (1996) reported that in Iceland (where all cases of autism are reported to the one institution, thereby maintaining minimal variations in diagnostic practices) the incidence rate has doubled over the last 20 years 2 Autism: An Epidemic? Rimland (1995) raised the possibility of an 'autism epidemic' Year % <3 yrs No. Children 65-'69 1 919 70-'79 5 4,184 80-'89 5 4,018 90-'93 8 6,785 94-'95 17 3,916 3 California Epidemic Increases Rick Rollens of the Mind Institute: August 2002 The California Department of Developmental Services recently reported another all time record number of children entering California's developmental services system who have received a professional diagnosis of DSM IV autism, not including PDD, NOS,Asperger's, or any other autism spectrum disorder such as rare genetic diseases like Fragile X 4 California Epidemic Increases A quarterly report for April-July 2002 showed that California added 846 children with level one DSM IV autism to its system This represents an all time record number of new cases for a quarterly report in the 31 year history of the system The report represents an 18% increase in new cases over the same quarter in the previous year and established autism as the number one disability This accounted for 40% of all intakes
    [Show full text]
  • Program Welcome
    The National Vaccine ThirdInternational Information Center PublicConferenceon Vaccination2002 November 7-9, 2002 CrystalGateway MarriottHotel Arlington,Virginia “Truth in Science: The Right to Know and The Freedom to Decide” Program Welcome DearFriends, As mothers of children, who suffered serious reactions to DPT vaccine and as co-founders of the National Vaccine Information Center, we welcome you to the Third International Public Conference on Vaccination. This year, the National Vaccine Information Center marks its 20th year of work to prevent vaccine injuries and deaths through public education. We are grateful to the many parents, grandparents and concerned citizens who support our work and have made it possible for so many distinguished speakers to share information with you. Our goal, as always, is to promote open and responsible discussion about what is and is not known about vaccination in order to encourage well designed research into the biological mechanisms of vaccine injury and death; the long term, chronic effects of multiple vaccination on individual and public health; the identification of genetic and other biological high risk factors; and the development of therapies to reduce or eliminate vaccine-induced neurological and immune system dysfunction. We also support the exploration of health care alternatives for preventing illness and maintaining health that are changing the face of medicine and providing new therapies for the vaccine injured. Finally, we are committed to defending the human right of all people to make informed, voluntary decisions about medical interventions which can cause injury or death, including vaccination. Our work and this conference is dedicated to the children, who had no voice and had no choice, and who lost their lives or their health and had their futures forever changed by public health policies promoted and enforced in the absence of adequate scientific knowledge about adverse responses to vaccination.
    [Show full text]
  • Thimerosal Exposure in Infants and Developmental Disorders: A
    Andrews, Nick et al. “Thimerosal Exposure in Infants and Developmental Disorders: A Retrospective Cohort Study in the United Kingdom Does Not Support a Causal Association.” Pediatrics 4.3 (Sep. 2004): 584-591. This is a U.K. retrospective cohort study that seeks to investigate whether infant reception of increasing thimerosal doses via the diphtheria-tetanus-whole-cell pertussis (DTP) and diphtheria-tetanus (DT) vaccines yields a subsequent risk for developing general developmental disorders. The U.S. EPA limit for daily ethylmercury (thimerosal) exposure is 0.1 µg/kg. But during the 1990’s, children receive a cumulative dose of 187 µg from vaccines by the age of 6 months, so it is important to assess whether high exposure to thimerosal is harmful to children. The U.K. administers much lower cumulative thimerosal doses, as DTP and DT are the only thimerosal-containing vaccines in the country. Although U.K. children receive lower cumulative doses, children in both countries receive about the same amount of thimerosal (150 µg) by age 3- 4 months, making comparison between these two countries highly reliable. “Exposure” in this study is defined as the number of DTP/DT doses received by age 3-4 months. Data for 109,863 U.K. children is analyzed between 1988 and 1997. The “outcome” encompasses all reports of general neurodevelopment disorders, including autism, behavior problems, speech delay, ADD, tics, encopresis, enuresis and other unspecified developmental delays. Hazard ratios (HRs) for each disorder are calculated per dose or per unit of cumulative DTP/DT vaccine exposure. The results find that the increasing doses DTP/DT actually offer a protective effect from general developmental disorders, speech delay and ADD.
    [Show full text]
  • Autism Report
    THE CALIFORNIA LEGISLATIVE BLUE RIBBON COMMISSION ON AUTISM REPORT An Opportunity to Achieve Real Change for Californians with Autism Spectrum Disorders SEPTEMBER 2007 THE CALIFORNIA LEGISLATIVE BLUE RIBBON COMMISSION ON AUTISM REPORT An Opportunity to Achieve Real Change for Californians with Autism Spectrum Disorders SEPTEMBER 2007 THE LEGIS L A T IVE OFFICE BUI L DING 1020 N ST REE T , Roo M 359 SACRAMEN to , CA L IF O RNIA 95814 Ph o n e 916-319-3541 • Fa x 916-319-3547 H tt P ://SENWE B 03.SEN .CA .G O V /AU T ISM The Honorable Arnold Schwarzenegger Governor of California The Honorable Don Perata The Honorable Dick Ackerman President pro Tempore of the Senate Senate Minority Leader and Members of the Senate The Honorable Fabian Núñez The Honorable Michael Villines Speaker of the Assembly Assembly Minority Leader and Members of the Assembly Dear Governor and Members of the Legislature: We are pleased to submit “The California Legislative Blue Ribbon Commission on Autism Report: An Opportunity to Achieve Real Change for Californians with Autism Spectrum Disorders.” The report details the findings and recommendations of the California Legislative Blue Ribbon Commission on Autism, pursuant to Senate Concurrent Resolution 51 (Perata), Resolution Chapter 124, Statutes of 2005. The Commission was established to study and investigate the early identification and intervention of autism spectrum disorders (ASD); gaps in programs and services related to the education and treatment of children, adolescents, transitional youth, and adults with ASD; and the planning required to address the “aging out” of children who comprise the current autism epidemic.
    [Show full text]
  • Newstrak Videotape Collection
    http://oac.cdlib.org/findaid/ark:/13030/c8zp4d11 No online items Guide to the NewsTrak videotape collection April Austin and Sean Heyliger Center for Sacramento History 551 Sequoia Pacific Blvd. Sacramento, California 95811-0229 Phone: (916) 808-7072 Fax: (916) 264-7582 Email: [email protected] URL: http://www.centerforsacramentohistory.org/ &#x00A9; 2013 Center for Sacramento History. All rights reserved. Guide to the NewsTrak videotape MS0037 1 collection Guide to the NewsTrak videotape collection Collection number: MS0037 Center for Sacramento History Sacramento, CA Processed by: April Austin and Sean Heyliger Date Completed: 10/04/2019 Encoded by: Sean Heyliger &#x00A9; 2013 Center for Sacramento History. All rights reserved. Descriptive Summary Title: NewsTrak videotape collection Dates: 1987-2006 Collection number: MS0037 Creator: NewsTrak Collection Size: 91 linear feet (91 boxes) Repository: Center for Sacramento History Sacramento, California 95811-0229 Abstract: The NewsTrak Videotape Collection consists 91 boxes of media coverage collected by the NewsTrak media monitoring firm from various television news stations, public relations firms, and government, corporate and non-profit public relations departments in the Sacramento area between 1987-2006. Media coverage includes media releases by local public relations firm Runyon, Saltzman & Einhorn, coverage of local and state politicians including Arnold Schwarzenegger, Gray Davis, and Pete Wilson during their terms as California governor, the Rodney King verdict, Proposition
    [Show full text]
  • Autism Advisory Task Force Report to the Governor of California and the California State Legislature Page I
    Autism Advisory Task Force Report to the Governor of California and the California State Legislature February 21, 2013 Submitted by the California Department of Managed Health Care in Fulfillment of the Requirements of Senate Bill 946 (Chapter 650, Statutes 2011), Health and Safety Code section 1374.74(c) DEPARTMENT OF Man STATE OF CALIFORNIA HeaItL re DEPARTMENT OF MANAGED HEALTH CARE February 21, 2013 The Honorable Edmund G. Brown, Jr. The Honorable Darrell Steinberg Governor President pro Tempore Office of the Governor California State Senate do State Capitol, Suite 1173 State Capitol, Room 205 Sacramento, CA 95814 Sacramento, CA 95814 The Honorable John Perez The Honorable Ed Hernandez, D.O. Speaker of the Assembly Chair, Health Committee California State Assembly California State Senate State Capitol, Room 219 State Capitol, Room 2191 Sacramento, CA 95814 Sacramento, CA 95814 The Honorable Bill Monning The Honorable Tony Strickland Chair, Health Committee Vice Chair, Health Committee California State Assembly California State Senate State Capitol, Room 6005 State Capitol, Room 4062 Sacramento, CA 95814 Sacramento, CA 95814 The Honorable Dan Logue Vice Chair, Health Committee California State Assembly State Capitol, Room 4158 Sacramento, CA 95814 RE: Report of the Autism Advisory Task Force Dear Sirs: The Department of Managed Health Care (DMHC) is pleased to present this Report of the Autism Advisory Task Force which was created from legislation authored by Senator Darrell Steinberg, SB 946 (Chapter 650, Statutes of 2011). The bill directed the Task Force to develop recommendations concerning medically necessary behavioral health treatment for individuals with autism, provider qualifications and training, and requirements that unlicensed individuals providing behavioral health treatment should meet in order to obtain licensure from the State.
    [Show full text]
  • MMR Vaccine, Thimerosal and Regressive Or Late Onset Autism (“Autistic Enterocolitis”)
    MMR Vaccine, Thimerosal and Regressive or Late Onset Autism (“Autistic Enterocolitis”) A Review of the Evidence for a Link Between Vaccination and Regressive Autism March 2006 David Thrower, 49, Ackers Road, Stockton Heath, Warrington, England 1 email [email protected] 2 Contents Executive Summary Part A: A Novel Syndrome 1. What Is Acquired Autism/Autistic Enterocolitis 2. The New Syndrome 3. Regression 4. Presentation by Dr. Andrew Wakefield, April 2005 5. Presentation by Dr. Arthur Krigsman, April 2005 6. Some Wider Points Part B: The Scale of the Autism Problem 7. The Financial Costs - Autism Is Costing The Taxpayer £$Billions 8. Overall Cost Estimates 9. Failure to Monitor Increases In UK Autism Numbers 10. “Now Almost Everyone Knows Someone Who’s Autistic” 11. Is Autism Increasing Due To Changes In Criteria? 12. DSM-IV Autistic Disorder 13. Pervasive Developmental Disorder Not Otherwise Specified 14. Asperger’s 15. Paper by Mark Blaxill, June 2001 16. University of Cambridge Research 17. UK National Autistic Society Estimates 18. Review by Blaxill of Rates 19. Report by Loynes, UK All Party Parliamentary Group, Dec. 2001 20. Report, “Autism In Schools”, UK National Autistic Society May 2002 21. Autism in Scottish Schools 22. Is Autism Increasing? - Some Official UK Pronouncements 23. Autism In The USA 24. Close-Up On California 25. Close-Up On New Jersey 26. “Explaining” The US Increases 27. The US Amish Community 28. Autism Elsewhere Part C: MMR 29. The Introduction of MMR 30. Sudden UK Withdrawal of Pluserix & Immravax Vaccines 31. Recognised Adverse Reactions to MMR 32. US Vaccine Adverse Events Reporting System (VAERS) 33.
    [Show full text]
  • The Geek Syndrome | WIRED
    The Geek Syndrome | WIRED STEVE SILBERMAN | SCIENCE The Geek Syndrome Autism—and its milder cousin Asperger's syndrome—is surging among the children of Silicon Valley. Are math-and-tech genes to blame? NICK IS BUILDING a universe on his computer. He's already mapped out his first planet: an anvil-shaped world Nick's father is a software engineer, and his mother is a computer programmer. They've known that Nick was an unusual child for a long time. He's infatuated with fantasy novels, but he has a hard time reading people. Clearly bright and imaginative, he has no friends his own age. His inability to pick up on hidden agendas makes him easy prey to certain cruelties, as when some kids paid him a few dollars to wear a ridiculous outfit to school. One therapist suggested that Nick was suffering from an anxiety disorder. Another said he had a speech impediment. Then his mother read a book called Asperger's Syndrome: A Guide for Parents and Professionals. In it, psychologist Tony Attwood describes children who lack basic social and motor skills, seem unable to decode body language and sense the feelings of others, avoid eye contact, and frequently launch into monologues about narrowly defined—and often highly technical—interests. Even when very young, these children become obsessed with order, arranging their toys in a regimented fashion on the floor and flying into tantrums when their 1 https://www.wired.com/2001/12/aspergers/ The Geek Syndrome | WIRED routines are disturbed. As teenagers, they're prone to getting into trouble with teachers and other figures of authority, partly because the subtle cues that define societal hierarchies are invisible to them.
    [Show full text]
  • “A Report by the Taskforce on Equity and Diversity for Regional Center Autism Services”
    THE SENATE SELECT COMMITTEE ON AUTISM & RELATED DISORDERS Chair, President pro Tempore Darrell Steinberg “A Report by the Taskforce on Equity and Diversity for Regional Center Autism Services” Submitted by Taskforce Staff: Lou Vismara, MD Bob Giovati Concepción Tadeo 2013-2014 Legislative Session (Blank page) TH£ S£NAT£ SELECT COMMITTE£ ON AUTISM & RELATED DISORDER~ ''A Preliminary Report by the Taskforce on Equity and Diversity for Regional Center Autism Services'' Submitted by Taskforce Staff: Lou Vismara, MD Bob Giovati Concepcion Tadeo (Blank page) Contents Executive Summary ..................................................................................... 1 Chapter 1 Overview of the Taskforce on Equity and Diversity for Regional Center Autism Services.......................................................................................... 5 Chapter 2 Existing Statutes and Regulations That Promote Equity, Diversity and Cultural Competence ............................................................................ 13 Chapter 3 Regional Centers Must Provide Information in a Linguistically and Culturally Competent Manner................................................................ 27 Chapter 4 Demographic Analysis of Purchase of Service Expenditures by the Regional Centers ................................................................................... 39 Chapter 5 Performance & Outcome Measures on Issues of Equity, Diversity and Cultural Competency...........................................................................
    [Show full text]
  • Autism--Why the Increased Rates? a One-Year Update. Hearings
    DOCUMENT RESUME ED 467 484 EC 309 127 TITLE Autism--Why the Increased Rates? A One-Year Update. Hearings before the Committee on Government Reform, House of Representatives, One Hundred Seventh Congress, First Session, April 25 and 26, 2001. INSTITUTION Congress of the U.S., Washington, DC. House Committee on Government Reform. REPORT NO House-Hrg-107-29 PUB DATE 2001-04-00 NOTE 397p. AVAILABLE FROM Superintendent of Documents, U.S. Government Printing Office, Mail Stop: SSOP, Washington, DC 20402-0001. Tel: 202 -512- 1800; Tel: 866-512-1800 (Toll Free); Fax: 202-512-2250. For full text: http://www.gpo.gov/congress/house. PUB TYPE Legal/Legislative/Regulatory Materials (090) EDRS PRICE EDRS Price MFO1 /PC16 Plus Postage. DESCRIPTORS *Autism; Comparative Analysis; Data Analysis; Epidemiology; Etiology; Hearings; *Immunization Programs; *Incidence; *Symptoms (Individual Disorders); *Trend Analysis IDENTIFIERS Congress 107th ABSTRACT These hearings before the House of Representatives Committee on Government Reform address possible reasons for the apparently rapid increase in the incidence of autism. An introduction by the Committee Chairman, Dan Burton, provides background information and suggests a possible linkage between autism and the mumps-measles-rubella vaccine, specifically the possibility of mercury contamination. Text is included of statements from representatives of the following: the Committee on Immunization Safety, Institute of Medicine; National Academy of Sciences; Indiana University School of Medicine; McGill University; MIND Institute, University of California, Davis; National Institute of Child Health and Human Development; Office of Vaccine Research and Review, Food and Drug Administration; Office of Vital Statistics and Epidemiology; and the Center on Birth Defects and Developmental Disabilities.
    [Show full text]
  • UC Santa Cruz UC Santa Cruz Electronic Theses and Dissertations
    UC Santa Cruz UC Santa Cruz Electronic Theses and Dissertations Title On The Spectrum: Autistics, Functioning, and Care Permalink https://escholarship.org/uc/item/8707b86c Author Moore, Matthew J Publication Date 2014 License https://creativecommons.org/licenses/by-nc-nd/4.0/ 4.0 Peer reviewed|Thesis/dissertation eScholarship.org Powered by the California Digital Library University of California UNIVERSITY OF CALIFORNIA SANTA CRUZ ON THE SPECTRUM: AUTISTICS, FUNCTIONING, AND CARE A dissertation submitted in partial satisfaction of the requirements for the degree of DOCTOR OF PHILOSOPHY in HISTORY OF CONSCIOUSNESS by Matthew John Moore June 2014 The Dissertation of Matthew Moore is approved: Distinguished Professor Emeritus James Clifford, Chair Distinguished Professor Emerita Donna Haraway Professor Emerita Adele Clarke Tyrus Miller Vice Provost and Dean of Graduate Studies Copyright © by Matthew J. Moore 2014 Contents List of Figures iv Abstract v Acknowledgments vii Introduction On the Spectrum: Autistics, Functioning, and Care 1 Chapter One Human Kind(s) in Motion: Articulations and 28 Idioms of Biosocial Becoming Chapter Two Beside the Autism Wars: Navigating an Epidemic 80 Chapter Three Meetings: Wrestling with Spectra 139 Chapter Four Critical Studies of Autism, Or: How I Learned to 205 Stop Worrying and Love Neuro-essentialism Conclusion Situated Functioning: Facilities and Difficulties 259 References 288 iii List of Figures 96 A 6,000% Increase in Autism 128 CDC: 1 in 68 Children 129 The Cost of Autism 133 Innovative Models for Funding: Working beyond the science to deliver the science 187 Cerebrum: Brains and Dollars 188 Psychiatry as a Clinical Neuroscience 228 Neurodiversity: A Symposium 263 Autism Parenting Magazine: Exposing Autism Speaks iv Abstract On the Spectrum: Autistics, Functioning, and Care Matthew J Moore University of California Santa Cruz On the Spectrum explores the recent flourishing of autistic self-advocates as social actors, stakeholders, and co-creators of autism worlds.
    [Show full text]
  • Transcript of Telehealth Hearing
    Senate Select Committee on Autism & Related Disorders Darrell Steinberg, Chair Technology & Autism Spectrum Disorders (ASD) “Adapting ‘Digital Age’ Innovations to Expand Access & to Improve Services for Individuals with ASD” February 22, 2012 State Capitol SENATOR DARRELL STEINBERG: Good morning, everybody. I want to welcome everyone to the Senate Select Committee Autism and Related Disorders. I’m Darrell Steinberg, the chair of the committee, and I want to thank all of my colleagues who are here today. You know, select committees sometimes get good attendance; oftentimes they don’t. And I think it speaks to the seriousness of these issues and the commitment of the membership— bipartisan, bicameral—welcome, Assemblymember Logue—that we tackle this. And those of you who have followed the history of this committee and its predecessor, the Blue Ribbon Task Force, know that this is not just a study committee. This is a committee that takes what we hear very seriously. And, like last year, with SB 946, we turned the testimony into action, and we hope we can do that again this year because, as much as we celebrate the success of the past year and past years, we know that the work on behalf of children of autism and their families is far from over. And here’s why it becomes even more poignant in why today’s hearing is so important: It’s no secret that our safety net system for individuals with autism and other disabilities are being significantly impacted by the state’s fiscal crisis. We don’t have to continue to recite the statistics.
    [Show full text]